Quantitative assessment of botulinum toxin injection on blink rate in blepharospasm

References

• Jankovic J, Kenney C, Grafe S, Goertelmeyer R, Comes G. Relationship between various clinical outcome assessments in patients with blepharospasm. Mov Disord. 2009;24(3):407–413. doi:10.1002/mds.22368.
   PubMed Web of Science ®Google Scholar
• Tucha O, Naumann M, Berg D, Alders GL, Lange KW. Quality of life in patients with blepharospasm. Acta Neurol Scand. 2001;103(1):49–52. doi:10.1034/j.1600-0404.2001.00109.x.
   PubMed Web of Science ®Google Scholar
• Anderson RL, Patel BC, Holds JB, Jordan DR. Blepharospasm: past, present, and future. Ophthalmic Plast Reconstr Surg. 1998;14(5):305–317. doi:10.1097/00002341-199809000-00002.
   PubMed Web of Science ®Google Scholar
• Lee S, Yen MT. Secondary blepharospasm associated with ocular surface disease. Int Ophthalmol Clin. 2018;58(1):71–75. doi:10.1097/IIO.0000000000000205.
   PubMedGoogle Scholar
• Gumus K, Lee S, Yen MT, Pflugfelder SC. Botulinum toxin injection for the management of refractory filamentary keratitis. Arch Ophthalmol. 2012;130(4):446–450. doi:10.1001/archophthalmol.2011.2713.
   PubMedGoogle Scholar
• Girard BC, Lévy P. Dry eye syndrome in benign essential blepharospasm. Journal Français d’Ophtalmologie. 2019;42(10):1062–1067. doi:10.1016/j.jfo.2019.06.007.
   PubMed Web of Science ®Google Scholar
• Lai KK, Kuk AK, Chan E, Ko ST. The good toxin: 10 years of experience with botulinum toxin a in the treatment of benign essential blepharospasm. Eur J Ophthalmol. 2021;31(3):1345–1350. doi:10.1177/1120672120925630.
   PubMed Web of Science ®Google Scholar
• Badarny S, Ibrahim R, Susel Z, Zaina A, Nasar R, Badarny Y. Long-term stable efficacy of botulinum toxin a in facial movement disorders with no need for increasing dose. Medicine. 2021;100(25):e26481. doi:10.1097/MD.0000000000026481.
   PubMed Web of Science ®Google Scholar
• Bilyk JR, Yen MT, Bradley EA, Wladis EJ, Mawn LA. Chemodenervation for the treatment of facial dystonia: a report by the American Academy of ophthalmology. Ophthalmology. 2018;125(9):1459–1467. doi:10.1016/j.ophtha.2018.03.013.
   PubMed Web of Science ®Google Scholar
• Yen MT. Developments in the treatment of benign essential blepharospasm. Curr Opin Ophthalmol. 2018;29(5):440–444. doi:10.1097/ICU.0000000000000500.
   PubMed Web of Science ®Google Scholar
• Truong D, Comella C, Fernandez HH, Ondo WG. Efficacy and safety of purified botulinum toxin type a (Dysport®) for the treatment of benign essential blepharospasm: a randomized, placebo-controlled, phase II trial. Parkinsonism Relat Disord. 2008;14(5):407–414. doi:10.1016/j.parkreldis.2007.11.003.
   PubMed Web of Science ®Google Scholar
• Lindeboom R, De Haan R, Aramideh M, Speelman JD. The blepharospasm disability scale: an instrument for the assessment of functional health in blepharospasm. Mov Disord. 1995;10(4):444–449. doi:10.1002/mds.870100407.
   PubMed Web of Science ®Google Scholar
• Roggenkämper P, Jost WH, Bihari K, Comes G, Grafe S. For the NTBST. Efficacy and safety of a new botulinum toxin type a free of complexing proteins in the treatment of blepharospasm. J Neural Transm. 2006;113(3):303–312. doi:10.1007/s00702-005-0323-3.
   PubMed Web of Science ®Google Scholar
• Defazio G, Hallett M, Jinnah HA, et al. Development and validation of a clinical scale for rating the severity of blepharospasm. Mov Disord. 2015;30(4):525–530. doi:10.1002/mds.26156.
   PubMed Web of Science ®Google Scholar
• Ferrazzano G, Conte A, Fabbrini G, et al. Botulinum toxin and blink rate in patients with blepharospasm and increased blinking. J Neurol Neurosurg Psychiatry. 2015;86(3):336–340. doi:10.1136/jnnp-2014-307821.
   PubMed Web of Science ®Google Scholar
• Gameiro G, Osaki M, Yabumoto C, et al. Do blinking parameters in essential blepharospasm patients become similar to normal subjects after botulinum toxin injections? Invest Ophthalmol Vis Sci. 2022;63. 608–A0309 .
   Web of Science ®Google Scholar
• Jang J, Lew H. Blink index as a response predictor of blepharospasm to botulinum neurotoxin-A treatment. Brain Behav. 2021;11(11):e2374. doi:10.1002/brb3.2374.
   PubMed Web of Science ®Google Scholar
• Mitchell T, Murri M, Pflugfelder SC. Video viewing blink rate in normal and dry eyes. Eye Contact Lens. 2021;47(8):442–444. doi:10.1097/ICL.0000000000000791.
   PubMed Web of Science ®Google Scholar
• Harrison AR, Berbos Z, Zaldivar RA, et al. Modulating neuromuscular junction density changes in botulinum toxin–treated orbicularis oculi muscle. Invest Ophthalmol Vis Sci. 2011;52(2):982–986. doi:10.1167/iovs.10-6427.
   PubMed Web of Science ®Google Scholar
• Choi WH, Song CW, Kim YB, et al. Skeletal muscle atrophy induced by intramuscular repeated dose of botulinum toxin type a in rats. Drug Chem Toxicol. 2007;30(3):217–227. doi:10.1080/01480540701375091.
   PubMed Web of Science ®Google Scholar
• Venkateswaran N, Hwang J, Rong AJ, et al. Periorbital botulinum toxin a improves photophobia and sensations of dryness in patients without migraine: case series of four patients. Am J Ophthalmol Case Rep. 2020;19:100809. doi:10.1016/j.ajoc.2020.100809.
   PubMedGoogle Scholar
• Girard B, de Saint Sauveur G. Tear osmolarity, dry eye syndrome, blepharospasm and botulinum neurotoxin. J Fr Ophtalmol. 2021;44(10):1553–1559. doi:10.1016/j.jfo.2021.05.009.
   PubMed Web of Science ®Google Scholar
• Lu R, Huang R, Li K, et al. The influence of benign essential blepharospasm on dry eye disease and ocular inflammation. Am J Ophthalmol. 2014;157(3):591–592. doi:10.1016/j.ajo.2013.11.014.
   PubMed Web of Science ®Google Scholar
• Park DI, Shin HM, Lee SY, Lew H. Tear production and drainage after botulinum toxin a injection in patients with essential blepharospasm. Acta Ophthalmol. 2013;91(2):e108–112. doi:10.1111/aos.12002.
   PubMed Web of Science ®Google Scholar
• Hosotani Y, Yokoi N, Okamoto M, et al. Characteristics of tear abnormalities associated with benign essential blepharospasm and amelioration by means of botulinum toxin type a treatment. Jpn J Ophthalmol. 2020;64(1):45–53. doi:10.1007/s10384-019-00705-3.
   PubMed Web of Science ®Google Scholar
• Horwath-Winter J, Bergloeff J, Floegel I, Haller-Schober EM, Schmut O. Botulinum toxin a treatment in patients suffering from blepharospasm and dry eye. Br J Ophthalmol. 2003;87(1):54–56. doi:10.1136/bjo.87.1.54.
   PubMed Web of Science ®Google Scholar
• Kocabeyoglu S, Sekeroglu HT, Mocan MC, Muz E, Irkec M, Sanac AS. Ocular surface alterations in blepharospasm patients treated with botulinum toxin a injection. Eur J Ophthalmol. 2014;24(6):830–834. doi:10.5301/ejo.5000482.
   PubMed Web of Science ®Google Scholar